Oncosec Medical Incorporated Quick Ratio (ONCS) starting from the second quarter 2022 to second quarter 2021, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Oncosec Medical Incorporated  (NASDAQ: ONCS)

Oncosec Medical Incorporated's Quick Ratio

ONCS's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2022, Quick Ratio fell to 0.51 below Oncosec Medical Incorporated average.

Within Major Pharmaceutical Preparations industry 527 other companies have achieved higher Quick Ratio than Oncosec Medical Incorporated in second quarter 2022. While Quick Ratio total ranking in the second quarter 2022 has deteriorated compared to the prior quarter from 2425 to 3013.

Explain Quick Ratio?
How much Cash & cash equivalents ONCS´s has?
What are ONCS´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ONCS Quick Ratio (Jan 31 2023)
Q2		 (Oct 31 2022)
Q1		 (Jul 31 2022)
Q4		 (Apr 30 2022)
Q3		 (Jan 31 2022)
Q2
Y / Y Current Liabilities Change 29.79 % 0.57 % -16.69 % -18.2 % -48.42 %
Y / Y Cash & cash equivalent Change -85.4 % -83.95 % -73.23 % -64.19 % -58.18 %
Quick Ratio MRQ 0.51 0.83 1.85 4.16 4.53
ONCS's Total Ranking # 3013 # 2425 # 2208 # 2217 # 571
Seq. Current Liabilities Change 4.65 % 4.16 % 41.53 % -15.88 % -18.9 %
Seq. Cash & cash equivalent Change -35.72 % -53.42 % -36.85 % -22.8 % -29.34 %



Quick Ratio second quarter 2022 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 528
Healthcare Sector # 983
Overall Market # 3013


Quick Ratio Statistics
High Average Low
30.92 6.75 0.11
(Oct 31 2014)   (Jan 31 2012)




Financial Statements
Oncosec Medical Incorporated's Current Liabilities $ 7 Millions Visit ONCS's Balance sheet
Oncosec Medical Incorporated's Cash & cash equivalent $ 4 Millions Visit ONCS's Balance sheet
Source of ONCS's Sales Visit ONCS's Sales by Geography


Cumulative Oncosec Medical Incorporated's Quick Ratio

ONCS's Quick Ratio for the trailling 12 Months

ONCS Quick Ratio

 (Jan 31 2023)
12 Months		 (Oct 31 2022)
12 Months		 (Jul 31 2022)
12 Months		 (Apr 30 2022)
12 Months		 (Jan 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth -2.57 % -24.11 % -33.18 % -32.69 % -38.14 %
Y / Y Cash & cash equivalent TTM Growth -74.46 % -68.05 % -49.79 % -20.55 % 19.7 %
Quick Ratio TTM 1.62 2.64 3.9 5.04 6.17
Total Ranking TTM # 4685 # 4609 # 1058 # 807 # 747
Seq. Current Liabilities TTM Growth 6.97 % 0.17 % -5.3 % -3.99 % -16.68 %
Seq. Cash & cash equivalent TTM Growth -34.35 % -32.33 % -26.63 % -21.65 % -17.87 %

Quick ratio ranking by company, industry and sector >> Back to ONCS Financial Strength Comparisons >> Go to Compare ONCS Quick Ratio to its Competitors

On the trailing twelve months basis Due to rise in Current Liabilities in the Q2 2022 to $7.23 millions, cumulative Quick Ratio decreased to 1.62 below the Oncosec Medical Incorporated average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 588 other companies have achieved higher Quick Ratio than Oncosec Medical Incorporated. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the first quarter 2022 from 4609 to 4685.

Explain Quick Ratio?
How much Cash & cash equivalents ONCS´s has?
What are ONCS´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 589
Healthcare Sector # 1188
Within the Market # 4685


trailing twelve months Quick Ratio Statistics
High Average Low
6.26 4.21 1.62
(Oct 31 2021)   (Jan 31 2023)




Companies with similar Quick Ratio in the quarter ending Jan 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioJan 31 2023 MRQ Cash & cash equivalentJan 31 2023 MRQ Current Liabilities
Fortress Biotech Inc   1.40 $ 178.266  Millions$ 127.715  Millions
Petros Pharmaceuticals inc   1.38 $ 9.426  Millions$ 6.812  Millions
Morphosys Ag  1.38 $ 450.633  Millions$ 326.645  Millions
Tiziana Life Sciences Ltd  1.37 $ 18.122  Millions$ 13.195  Millions
Inflarx N V  1.36 $ 19.821  Millions$ 14.589  Millions
Bellerophon Therapeutics inc  1.36 $ 7.329  Millions$ 5.401  Millions
Durect Corp  1.35 $ 43.483  Millions$ 32.172  Millions
Organogenesis Holdings Inc   1.34 $ 102.478  Millions$ 76.655  Millions
Clever Leaves Holdings Inc   1.32 $ 12.449  Millions$ 9.426  Millions
Elicio Therapeutics Inc   1.32 $ 6.257  Millions$ 4.740  Millions
Biora Therapeutics Inc   1.31 $ 30.486  Millions$ 23.305  Millions
Talphera Inc   1.29 $ 15.770  Millions$ 12.228  Millions
Elite Pharmaceuticals Inc   1.29 $ 8.627  Millions$ 6.694  Millions
Nrx Pharmaceuticals Inc   1.29 $ 20.054  Millions$ 15.585  Millions
Avadel Pharmaceuticals Plc  1.28 $ 73.981  Millions$ 57.976  Millions
Stablecoin Development Corporation  1.26 $ 5.362  Millions$ 4.257  Millions
Wave Life Sciences Ltd   1.24 $ 88.497  Millions$ 71.521  Millions
Cytomx Therapeutics Inc   1.23 $ 193.650  Millions$ 157.795  Millions
Evotec Se  1.23 $ 525.926  Millions$ 428.630  Millions
Alkermes Plc   1.22 $ 608.465  Millions$ 497.742  Millions
Rockwell Medical inc   1.21 $ 21.492  Millions$ 17.691  Millions
Celyad Oncology Sa  1.19 $ 13.938  Millions$ 11.677  Millions
Ascendis Pharma A  1.16 $ 499.128  Millions$ 428.975  Millions
Evolus Inc   1.16 $ 53.922  Millions$ 46.509  Millions
Kineta Inc   1.14 $ 13.143  Millions$ 11.487  Millions
Transcode Therapeutics Inc   1.14 $ 4.968  Millions$ 4.347  Millions
Quantum Biopharma Ltd   1.14 $ 16.980  Millions$ 14.939  Millions
Myovant Sciences Ltd   1.12 $ 274.437  Millions$ 245.753  Millions
Sellas Life Sciences Group Inc   1.11 $ 17.225  Millions$ 15.515  Millions
Nanobiotix S a   1.09 $ 46.355  Millions$ 42.488  Millions

Date modified: 2026-09-08T15:10:51+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.